Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1256 results about "Metabolic disorder" patented technology

A metabolic disorder can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive.

GLP-1R and GCGR double-target-activated polypeptide or derivative thereof, pharmaceutically acceptable salt and application of polypeptide or derivative and pharmaceutically acceptable salt

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in treating metabolic disorders

The present disclosure relates to the treatment of metabolic disorders, such as metabolic syndrome, obesity, and type 2 diabetes. Adjunct therapies and combination therapies that include a myostatin pathway inhibitor, used in conjunction with a GLP-1 pathway activator are disclosed.
Owner:SCHOLAR ROCK INC

GLP-1R activating polypeptide or pharmaceutically acceptable salt thereof and application thereof

The invention provides a polypeptide or a pharmaceutically acceptable salt of the polypeptide. The amino acid sequence of the polypeptide is as shown in HSQGTFTSDYSKYLEEAAAAEFVAWLLAGG. The invention further provides a preparation method of the polypeptide. The polypeptide or the pharmaceutically acceptable salt thereof can be combined with the GLP-1R and is used for effectively activating the GLP-1R. Therefore, the polypeptide or the pharmaceutically acceptable salt thereof can be used for effectively treating metabolic disorder related diseases (such as obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes and non-alcoholic fatty liver diseases).
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

Application of Ackermania muciniphila YG2645 in improvement of glycolipid metabolism

The invention relates to application of Akkermansia muciniphila YG2645 or a derivative of the Akkermansia muciniphila YG2645 or a composition containing the Akkermansia muciniphila YG2645 to preparation of a product for improving glycolipid metabolism disorder or treating diseases or symptoms related to the glycolipid metabolism disorder. The Ackermansiella muciniphila can effectively inhibit lipid accumulation, promote GLP-1 secretion, regulate intestinal flora and regulate cholic acid, taurine and phospholipid metabolism, so that the Ackermansiella muciniphila has potential treatment potential in the aspects of regulating glycolipid metabolism disorder and treating diseases or symptoms related to the glycolipid metabolism disorder, and has better clinical application prospect and value.
Owner:BEIJING YUJING PHARM CO LTD

Substituted piperidinediones for targeted protein degradation

PCT designated stage expiredWO2025024521A1Organic active ingredientsAntipyreticInterstitial lung diseasePericarditis
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:MONTE ROSA THERAPEUTICS AG

Methods and compositions for diagnosis and treatment of metabolic disorders

Most disease-associated genetic loci map to more than one disease or trait, suggesting they act through multiple cell types and tissues giving rise to complex disease phenotypes. This pervasive pleiotropy of human diseases presents a tremendous burden on identifying mediating mechanisms and therapeutic targets. Multiple metabolic risk haplotypes are associated with risk for metabolic diseases. However, whether a haplotype actually causes a disease and the mechanisms that cause the disease are unknown. Integration of phenotypic and transcriptional profiling in primary human cells allows for functional characterization of disease-associated genetic variants. Applicants have analyzed multiple risk haplotypes and determined the function of risk haplotypes involved in causation of specific metabolic phenotypes, such as type 2 diabetes and lipodystrophy. Methods of treatments are disclosed herein.
Owner:THE BROAD INST INC +1

Phenolic composite resistant starch capable of efficiently regulating blood sugar as well as preparation method and application of phenolic composite resistant starch

The invention discloses phenolic composite resistant starch capable of efficiently regulating blood sugar as well as a preparation method and application of the phenolic composite resistant starch. The phenolic composite resistant starch has a V6 and V7 polymorphic structure, good thermal stability, good enzyme resistance, enzyme activity inhibition and glucose transport inhibition capability, and the preparation method is simple in process operation. The functional resistant starch disclosed by the invention can be used for preparing various products with the effects of regulating postprandial blood sugar and preventing and improving related metabolic disorders / diseases such as diabetes and the like.
Owner:TIANJIN UNIV OF SCI & TECH

Application of HERP gene knockout mouse model in obesity and metabolic disorder diseases

The invention discloses an application of an HERP gene knockout mouse model in obesity and metabolic disorder diseases. The invention finds that compared with a wild type high-fat group, HERP gene knockout can cause phenotypes such as early obesity, more serious obesity degree, increase of fat weight ratio, aggravation of adipose tissue inflammation, dyslipidemia and glucose metabolism disorder of mice during high-fat feeding. And the HERP gene is knocked out, so that the adipocyte differentiation is increased. The HERP gene knockout mouse is more sensitive to nutrition, obesity can occur more quickly during high-fat feeding, symptoms such as fat amplification, fat inflammation and glucose and lipid metabolism disorder are more serious, and the HERP gene knockout mouse can be used for molecular mechanism research and drug screening of obesity, fat tissue and glucose and lipid metabolism disorder. It is further found that cilostazol can significantly relieve mouse obesity and lipid metabolism disorder caused by HERP gene defects, but has no obvious weight losing effect on normal genotype mice, and a new strategy is provided for precise treatment.
Owner:THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV

Feed functional compound for improving saline-alkaline stress resistance of macrobrachium rosenbergii and application of feed functional compound

The invention discloses a feed functional compound for improving salt-alkali stress resistance of macrobrachium rosenbergii and application of the feed functional compound, and belongs to the technical field of aquaculture. The feed functional compound for improving saline-alkaline stress resistance of macrobrachium rosenbergii provided by the invention comprises vitamin D3, betaine and sodium oleate. According to the invention, the absorption promotion effect of vitamin D3 on calcium and phosphorus ions is utilized, so that the ion metabolism disorder of macrobrachium rosenbergii under saline-alkali stress is improved; by utilizing the osmotic pressure regulation capability of betaine, osmotic pressure unbalance under saline-alkali stress is improved, and the energy consumption of osmotic regulation is reduced; the sodium oleate is used for improving energy supply, the membrane structure is adjusted to improve osmotic pressure adjusting capacity, and the three components act together to achieve the purpose of improving salt-alkali stress tolerance of macrobrachium rosenbergii.
Owner:ZHEJIANG DANSHUI FISHERY RESEARCH INSTITUTE (ZHEJIANG DANSHUI FISHERY ENVIRONMENTAL MONITORING STATION)

Antibody conjugates and fusion proteins

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.
Owner:SIXPEAKS BIO AG

Pediococcus acidilactici XZ106 and application thereof

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.
Owner:SOUTHWEST UNIV

Tricyclic compound, and preparation method therefor and use thereof

A tricyclic compound, and a preparation method therefor and the use thereof. The present invention relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, genetic disorders, hormone-related diseases, metabolic disorders, organ-transplantation-related diseases, immunodeficiency disorders, destructive bone diseases, proliferative disorders, infectious diseases, cell-death-related conditions and cardiovascular diseases. Each substituent in general formula (I) is as defined in the description.
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD

Protein-based delivery system

PCT designated stage expiredWO2025019713A2Connective tissue peptidesAntibody mimetics/scaffoldsElastin like polypeptidesRespiratory disease
Provided herein are elastin-like polypeptides, endosomal escape peptides, and compounds comprising an elastin-like polypeptide chemically or recombinantly conjugated to one or more endosomal escape peptides. Also provided herein are compositions comprising a compound provided herein and an agent, methods of delivering an agent, and methods of treating or preventing a disease (e.g., a cardiovascular disease, a lung or respiratory disease, a musculoskeletal disease, a hematological disease, an immune disorder, an infectious disease, a genetic disease, cancer, a neurological disease, a psychiatric disorder, a metabolic disorder, or an inflammatory disease).
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC

Phytobacterium plantarum BD7807 and application thereof in treatment of lipid metabolism disorder

The invention relates to the technical field of microorganisms, in particular to a plant lactobacillus BD7807 and application thereof in treating lipid metabolism disorder, and particularly discloses a plant lactobacillus BD7807 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.33630. The invention further discloses a preparation method of the plant lactobacillus BD7807. The plant lactobacillus BD7807 has obvious lipid-lowering, anti-oxidation and adhesion capabilities, is bacteriostatic, has no multiple drug resistance, can play a role in lowering lipid without damaging other organs, and can be widely used for preventing and treating related symptoms caused by lipid metabolism disorder.
Owner:BRIGHT DAIRY & FOOD CO LTD

Edible and medicinal composition for dispelling effects of alcohol and protecting liver as well as preparation method and application of edible and medicinal composition

The invention discloses an edible and medicinal composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and belongs to the technical field of functional foods. The composition consists of the following raw materials in parts by weight: 1-8 parts of ampelopsis grossedentata extract freeze-dried powder, 1-8 parts of astragalus membranaceus extract freeze-dried powder, 1-5 parts of kudzu vine root extract freeze-dried powder, 1-8 parts of hawthorn extract freeze-dried powder and 1-5 parts of cassia seed extract freeze-dried powder. The composition is designed according to a multi-component synergistic interaction principle, and the functions of protecting the liver and dispelling the effects of alcohol are enhanced through targeted interaction of active ingredients such as ampelopsis grossedentata flavone, puerarin and astragaloside; the compound preparation has the compound effects of protecting the liver, dispelling the effects of alcohol, resolving dampness, resisting oxidative stress, regulating lipid metabolism and the like, can remarkably relieve the problems of acute and chronic liver injury and metabolic disorder caused by alcohol intake, and meets the food-grade safety standard and the medicinal activity requirement; the important application prospect is realized in the aspect of preparing a preparation for relieving alcoholic liver injury and improving the liver detoxification function.
Owner:NANJING JIANKE TONGCHUANG BIOTECHNOLOGY CO LTD +1

GLP1R activating polypeptide or pharmaceutically acceptable salt thereof and application thereof

The invention discloses a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence in a conservative modification form thereof. The polypeptide or the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP1R and is used for effectively activating the GLP1R. The GLP1R activating polypeptide is obtained through precise calculation and deep learning model optimization, has a short sequence, has unique amino acid arrangement compared with a traditional GLP-1 analogue, can effectively activate a GLP1R receptor, can also be used for treating or preventing metabolic disorder related diseases, and has a good application prospect. For example, obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes, non-alcoholic fatty liver diseases and the like.
Owner:TENCENT TECHNOLOGY (SHENZHEN) CO LTD

Genetically engineered mesenchymal stem cells and uses thereof

Disclosed herein is a genetically engineered mesenchymal stem cells (MSC) comprising genetic alterations that increase gene expressions for adipogenic differentiation, mitochondrial biogenesis and a brown adipocyte marker. Also disclosed herein is a pharmaceutical composition and use of the pharmaceutical composition for preventing, ameliorating and / or treating a metabolic disorder.
Owner:CHINA MEDICAL UNIVERSITY(TW)

Activin receptor type IIB variants and uses thereof

PCT designated stage expiredWO2025019954A1Polypeptide with localisation/targeting motifAntibody mimetics/scaffoldsTruncal muscle weaknessCardiometabolic disease
There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).
Owner:35PHARMA INC

Activin receptor type IIB variants and uses thereof

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).
Owner:35PHARMA INC +4

Indolizine compounds for the treatment of mental disorders or inflammation

The present invention discloses compounds, compositions, methods for modulating central nervous system activity, methods for treating inflammatory or metabolic disorders, and methods for treating central nervous system disorders, such as depression, anxiety, and trauma- and stressor-related disorders, comprising the indolizines having the structures disclosed herein.
Owner:TACTOGEN INC

Methods for therapeutic use of exosomes and Y-RNAS

Some embodiments of the methods and compositions provided herein relate to treating a subject suffering from hypertension, a cardiac injury, or a metabolic disorder. Some embodiments include administering an exosome to a subject. Some embodiments include administering an oligonucleotide to the subject. In some embodiments, the oligonucleotide comprises a Y-RNA or Y-RNA fragment such as EV-YF1 or EV-YF1-U16. In some embodiments, the oligonucleotide or exosome also has a therapeutic effect on the subject.
Owner:CEDARS SINAI MEDICAL CENT

Establishment method of animal model for age-related retinopathy caused by lipid metabolism disorder

The invention discloses a method for establishing an animal model for age-related retinopathy caused by lipid metabolism disorder, and the animal model is obtained by specifically knocking out Lss genes from mouse retinal pigment epithelium (RPE) cells by means of a CRISPR / Cas9 gene editing technology. The age-related retinopathy model mouse constructed by the invention shows a retinopathy phenotype with retinal lipid deposition and reduced visual function at the age of 5 months, and the retinopathy is further aggravated along with the increase of the age of the mouse and is similar to the phenotype of age-related retinopathy related to lipid metabolism disorder clinically; and an ideal and effective animal model is provided for researching age-related retinopathy.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Dsrna, use thereof, and preparation method therefor

The present invention relates to modulators that can regulate, for example, inhibit the expression and / or activity of an inhibin subunit βE (INHBE), such as double-stranded RNA (dsRNA) active agents or antisense polynucleotide formulations. The present invention also relates to a method for inhibiting the expression and / or activity of INHBE by using such modulators, and a method for preventing and treating INHBE-related diseases in subjects (such as metabolic disorders or obesity or cardiovascular diseases, such as metabolic syndrome).
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD

GLP-1, GIP and GCG receptor triagonist and use thereof

PCT designated stage expiredWO2025016303A1Metabolism disorderPeptide/protein ingredientsDiseaseInsulinotropin
A GLP-1, GIP and GCG receptor triagonist and a use thereof. The corresponding compound has an agonist effect on a human glucagon-like peptide-1 (GLP-1) receptor, a human glucose-dependent insulinotropic polypeptide (GIP) receptor and a human glucagon (GCG) receptor, and can be used for preventing and / or treating diseases or conditions related to metabolic disorders.
Owner:BEIJING TUO JIE BIOPHARMACEUTICAL CO LTD